secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0001104659-24-121616
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune submits BLA for RP1+nivolumab in advanced melanoma under Accelerated Approval; FDA grants Breakthrough Therapy
--------------------------------------------------------------------------------

- BLA submitted to FDA for RP1 (vusolimogene oderparepvec) + nivolumab in advanced melanoma patients previously treated with anti-PD1.
- Submission under Accelerated Approval pathway; based on safety and activity in IGNYTE trial.
- FDA granted Breakthrough Therapy designation for RP1 + nivolumab in same setting.
- Confirmatory Phase 3 IGNYTE-3 trial enrolling patients with prior anti-PD1 and anti-CTLA-4 therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924121616/0001104659-24-121616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924121616/tm2429181d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-121616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer